Overview

Study Evaluating GS-5245 in Nonhospitalized Participants With COVID-19

Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to test if GS-5245 is safe and effective for the treatment of COVID-19 in participants who have a standard risk of developing severe illness. The study will also measure how much GS-5245 gets into the blood and how long it takes for the body to get rid of it.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences